Literature DB >> 19694731

Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.

Rongjian Zhang1, Youhua Xu, Hong Fu, Juejin Wang, Lai Jin, Shengnan Li.   

Abstract

BACKGROUND AND
PURPOSE: Our previous study showed that urocortin (Ucn1) exacerbates the hypercoagulable state and vasculitis in a rat model of sodium laurate-induced thromboangiitis obliterans. Furthermore, the inflammatory molecules COX-2 and ICAM-1 may participate in this effect. In the present study, the effects of Ucn1 on COX-2 and ICAM-1 expression in lipopolysaccharide (LPS)-induced rat aortic endothelial cells (RAECs) were investigated and the mechanisms involved explored. EXPERIMENTAL APPROACH: RAECs were isolated from adult male Wistar rats, and identified at the first passage. Experiments were performed on cells, from primary culture, at passages 5-8. The expression of COX-2 and ICAM-1 at both mRNA and protein levels was determined by semi-quantitative RT-PCR and Western blot analysis. Levels of PGE(2) and soluble ICAM-1 (sICAM-1) in culture medium were measured by enzyme-linked immunosorbent assay. Furthermore, the phosphorylation status of p38MAPK, ERK1/2, JNK, Akt and NF-kappaB was analysed by Western blot; nuclear translocation of NF-kappaB was observed by immunofluorescence. KEY
RESULTS: Ucn1 augmented LPS-induced expression of COX-2 and ICAM-1 in RAECs in a time- and concentration-dependent manner. Ucn1 increased PGE(2) and sICAM-1 levels. These effects were abolished by the CRF(2) receptor antagonist, antisauvagine-30, but not by the CRF(1) receptor antagonist, NBI-27914. Moreover, Ucn2 activated p38MAPK and augmented NF-kappaB nuclear translocation and phosphorylation, whereas ERK1/2, JNK and Akt pathways were not involved in this process. CONCLUSIONS AND IMPLICATIONS: These findings suggest that Ucn1 exerts pro-inflammatory effects by augmenting LPS-induced expression of COX-2 and ICAM-1 in RAECs via CRF(2) receptors and the activation of p38MAPK and NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694731      PMCID: PMC2765601          DOI: 10.1111/j.1476-5381.2009.00346.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  65 in total

1.  NO regulates LPS-stimulated cyclooxygenase gene expression and activity in pulmonary artery endothelium.

Authors:  J X Chen; L C Berry; B W Christman; M Tanner; P R Myers; B O Meyrick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-03       Impact factor: 5.464

2.  Soluble ICAM-1: a marker of vascular inflammation and lifestyle.

Authors:  Anna Maria Witkowska
Journal:  Cytokine       Date:  2005-07-21       Impact factor: 3.861

Review 3.  Signal transduction pathways of inflammatory gene expressions and therapeutic implications.

Authors:  Ching-Chow Chen
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

4.  Lipopolysaccharide-induced apoptosis of endothelial cells and its inhibition by vascular endothelial growth factor.

Authors:  Neru Munshi; Aaron Z Fernandis; Rama P Cherla; In-Woo Park; Ramesh K Ganju
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

5.  Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects.

Authors:  T C Theoharides; L K Singh; W Boucher; X Pang; R Letourneau; E Webster; G Chrousos
Journal:  Endocrinology       Date:  1998-01       Impact factor: 4.736

6.  Expression of urocortin in rat lung and its effect on pulmonary vascular permeability.

Authors:  Yuqing Wu; Yinyan Xu; Hong Zhou; Jin Tao; Shengnan Li
Journal:  J Endocrinol       Date:  2006-04       Impact factor: 4.286

Review 7.  Localization and physiological roles of urocortin.

Authors:  Yutaka Oki; Hironobu Sasano
Journal:  Peptides       Date:  2004-10       Impact factor: 3.750

8.  Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts.

Authors:  Lu Gao; Chunmei Lu; Chen Xu; Yi Tao; Binhai Cong; Xin Ni
Journal:  Endocrinology       Date:  2008-03-06       Impact factor: 4.736

Review 9.  Urocortin: a beneficial or detrimental agent to endothelium?

Authors:  Cui Yang; Yinyan Xu; Shengnan Li
Journal:  Biochem Biophys Res Commun       Date:  2008-02-11       Impact factor: 3.575

10.  Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation.

Authors:  C C Chen; C L Rosenbloom; D C Anderson; A M Manning
Journal:  J Immunol       Date:  1995-10-01       Impact factor: 5.422

View more
  5 in total

Review 1.  Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?

Authors:  Huayuan Zhu; Juejin Wang; Jianyong Li; Shengnan Li
Journal:  Inflamm Res       Date:  2011-04-08       Impact factor: 4.575

2.  Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection.

Authors:  Xiu-Fang Gao; Yue Zhou; Da-Ying Wang; Kar-Sheng Lew; Arthur Mark Richards; Peipei Wang
Journal:  Mol Cell Biochem       Date:  2014-09-23       Impact factor: 3.396

3.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

4.  Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.

Authors:  Akinori Hasegawa; Kengo Sato; Remina Shirai; Rena Watanabe; Keigo Yamamoto; Kaho Watanabe; Kyoko Nohtomi; Tsutomu Hirano; Takuya Watanabe
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 5.  A Systematic Review of the Anti-Inflammatory and Immunomodulatory Properties of 16 Essential Oils of Herbs.

Authors:  Xu Zuo; Yinuo Gu; Chao Wang; Jinrong Zhang; Jing Zhang; Guoqiang Wang; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-07       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.